Cardiac 123I-MIBG scintigraphy can assess the disease severity and phenotype of PD

Journal of the Neurological Sciences

Volumn 220, Issue 1-2, 2004, Pages 105-111

  Saiki, Shinji ^a   Hirose, Genjiro ^a   Sakai, Koichiro ^a   Kataoka, Satoshi ^a   Hori, Ariyuki ^a   Saiki, Misuzu ^a   Kaito, Muichi ^a   Higashi, Kotaro ^a   Taki, Suzuka ^a   Kakeshita, Kazuo ^a   Fujino, Susumu ^b   Miaki, Miho ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

^b Fukui Prefectural Hospital   (Japan)

Author keywords

Cardiac MIBG scintigraphy; Parkinson's disease; PD phenotype; Unified Parkinson's Disease Rating Scale

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE; DIAGNOSTIC AGENT; ENZYME INHIBITOR; RADIOACTIVE IODINE;

ADULT; AGED; ARTICLE; BODY POSTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DISEASE SEVERITY; FEMALE; GAIT DISORDER; HEART; HEART SCINTISCANNING; HUMAN; MALE; MEDIASTINUM; ONSET AGE; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; RADIODIAGNOSIS; RATING SCALE; SHY DRAGER SYNDROME; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREMOR; ANALYSIS OF VARIANCE; ATAXIA; CASE CONTROL STUDY; COMPARATIVE STUDY; DRUG EFFECT; HOSPITALIZATION; METHODOLOGY; MIDDLE AGED; NEUROLOGIC EXAMINATION; NONPARAMETRIC TEST; PATHOPHYSIOLOGY; REGRESSION ANALYSIS; SCINTISCANNING;

3-IODOBENZYLGUANIDINE; ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; ENZYME INHIBITORS; FEMALE; GAIT ATAXIA; HEART; HUMANS; IODINE RADIOISOTOPES; LEWY BODY DISEASE; MALE; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; PHENOTYPE; RADIONUCLIDE IMAGING; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREMOR;

EID: 18344398295     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2004.02.018     Document Type: Article

References (43)

1. Kline R.C., Swanson D.P., Wieland D.M., et al. Myocardial imaging in man with I-123 meta-iodobenzylguanidine. J. Nucl. Med. 22:1981;129-132
2. Dae M.W., O'Connell J.W., Botvinick E.H., et al. Scintigraphic assessment of regional cardiac adrenergic innervation. Circulation. 79:1989;634-644
3. Langer A., Freeman M.R., Josse R.G., et al. Metaiodobenzylguanidine imaging in diabetes mellitus: assessment of cardiac sympathetic denervation and its relation to autonomic dysfunction and silent myocardial ischemia. J. Am. Coll. Cardiol. 25:1995;610-618
4. Hirayama M., Hakusui S., Koike Y., et al. A scintigraphical qualitative analysis of peripheral vascular sympathetic function with meta-[123I] iodobenzylguanidine in neurological patients with autonomic failure. J. Auton. Nerv. Syst. 53:1995;230-234
5. Takano H., Yoshimura N. Markedly decreased cardiac uptake with 123I-MIBG scintigraphy in a case of pure progressive autonomic failure. Rinsho Shinkeigaku. 33:1993;784-786
6. Nakata T., Shimamoto K., Yonekura S., et al. Cardiac sympathetic denervation in transthyretin-related familial amyloidotic polyneuropathy: detection with iodine-123-MIBG. J. Nucl. Med. 36:1995;1040-1042
7. Hongo M., Urushibata K., Kai R., et al. Iodine-123 metaiodobenzylguanidine scintigraphic analysis of myocardial sympathetic innervation in patients with AL (primary) amyloidosis. Am. Heart J. 144:2002;122-129
8. Iwasa K., Nakajima K., Yoshikawa H., et al. Decreased myocardial 123I-MIBG uptake in Parkinson's disease. Acta Neurol. Scand. 97:1998;303-306
9. Satoh A., Serita T., Seto M., et al. Loss of 123I-MIBG uptake by the heart in Parkinson's disease: assessment of cardiac sympathetic denervation and diagnostic value. J. Nucl. Med. 40:1999;371-375
10. Braune S., Reinhardt M., Bathmann J., et al. Impaired cardiac uptake of meta-[123I] iodobenzylguanidine in Parkinson's disease with autonomic failure. Acta Neurol. Scand. 97:1998;307-314
11. Orimo S., Ozawa E., Nakade S., et al. 123I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 67:1999;189-194
12. Takatsu H., Nishida H., Matsuo H., et al. Cardiac sympathetic denervation from the early stage of Parkinson's disease: clinical and experimental studies with radiolabeled MIBG. J. Nucl. Med. 41:2000;71-77
13. Braune S., Reinhardt M., Schnitzer R., et al. Cardiac uptake of [123I]MIBG separates Parkinson's disease from multiple system atrophy. Neurology. 53:1999;1020-1025
14. Taki J., Nakajima K., Hwang E.H., et al. Peripheral sympathetic dysfunction in patients with Parkinson's disease without autonomic failure is heart selective and disease specific. Eur. J. Nucl. Med. 27:2000;566-573
15. Hamada K., Hirayama M., Watanabe H., et al. Onset age and disease severity of motor impairment are associated with reduction of myocardial 123I-MIBG uptake in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 74:2003;423-426
16. Yoshita M. Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. Neurol. Sci. 155:1998;60-67
17. Druschky A., Hilz M.J., Platsch G., et al. Differentiation of Parkinson's disease and multiple system atrophy in early disease stages by means of I-123-MIBG-SPECT. J. Neurol. Sci. 175:2000;3-12
18. Fahn S., Elton R. Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. Fahn S., Marsden C.D., Calne D.B., Goldstein M. Recent developments in Parkinson's disease. vol. 2:1987;153-163 Macmillan, New Jersey
19. Mitchell S.L., Harper D.W., Lau A., et al. Patterns of outcome measurement in Parkinson's disease clinical trials. Neuroepidemiology. 19:2000;100-108
20. Hughes A.J., Daniel S.E., Kilford L., et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry. 55:1992;181-184
21. Gilman S., Low P.A., Quinn N., et al. Consensus statement on the diagnosis of multiple system atrophy. J. Neurol. Sci. 163:1999;94-98
22. McKeith I.G., Ballard C.G., Perry R.H., et al. Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology. 54:2000;1050-1058
23. Solanki K.K., Bomanji J., Moyes J., et al. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl. Med. Commun. 13:1992;513-521
24. Hoehn M.M., Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology. 17:1967;427-442
25. Jankovic J., Kapadia A.S. Functional decline in Parkinson disease. Arch. Neurol. 58:2001;1611-1615
26. Booij J., Tissingh G., Winogrodzka A., et al. Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Eur. J. Nucl. Med. 26:1999;171-182
27. Hishikawa N., Hashizume Y., Yoshida M., et al. Clinical and neuropathological correlates of Lewy body disease. Acta Neuropathol. 105:2003;341-350
28. Wakabayashi K., Takahashi H., Ohama E., et al. Lewy bodies in the visceral autonomic nervous system in Parkinson's disease. Narabayashi H., Nagatsu N., Yanagisawa N., Mizuno Y. Advances in neurology. 1993;609-612 Lippincott-Raven, New York
29. Iwanaga K., Wakabayashi K., Yoshimoto M., et al. Lewy body-type degeneration in cardiac plexus in Parkinson's and incidental Lewy body diseases. Neurology. 52:1999;1269-1271
30. Goldstein D.S., Holmes C., Cannon R.O. III, Eisenhofer G., Kopin I.J. Sympathetic cardioneuropathy in dysautonomias. N. Engl. J. Med. 336:1997;696-702
31. Goldstein D.S., Holmes C., Li S.T., et al. Cardiac sympathetic denervation in Parkinson disease. Ann. Intern. Med. 133:2000;338-347
32. Ramaker C., Marinus J., Stiggelbout A.M., et al. Systematic evaluation of rating scales for impairment and disability in Parkinson's disease. Mov. Disord. 17:2000;867-876
33. Ganguly P.K., Beamish R.E., Dhalla K.S., et al. Norepinephrine storage, distribution, and release in diabetic cardiomyopathy. Am. J. Physiol. 252:1987;E734
34. Delahaye N., Dinanian S., Slama M.S., et al. Cardiac sympathetic denervation in familial amyloid polyneuropathy assessed by iodine-123 metaiodobenzylguanidine scintigraphy and heart rate variability. Eur. J. Nucl. Med. 26:1999;416-424
35. Santamaria J., Tolosa E., Valles A. Parkinson's disease with depression: a possible subgroup of idiopathic parkinsonism. Neurology. 36:1986;1130-1133
36. Dubois B., Pillon B., Sternic N., et al. Age-induced cognitive disturbances in Parkinson's disease. Neurology. 40:1990;38-41
37. Starkstein S.E., Berthier M.L., Bolduc P.L., et al. Depression in patients with early versus late onset of Parkinson's disease. Neurology. 39:1989;1441-1445
38. Jankovic J., McDermott M., Carter J., et al. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort, The Parkinson Study Group. Neurology. 40:1990;1529-1534
39. Gibb W.R., Lees A.J. A comparison of clinical and pathological features of young- and old-onset Parkinson's disease. Neurology. 38:1988;1402-1406
40. Hietanen M., Teräväinen H. The effect of age of disease onset on neuropsychological performance in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 51:1988;244-249
41. Diamond S.G., Markham C.H., Hoehn M.M., et al. Effect of age at onset on progression and mortality in Parkinson's disease. Neurology. 39:1989;1187-1190
42. Zetusky W.J., Jankovic J., Pirozzolo F.J. The heterogeneity of Parkinson's disease: Clinical and prognostic implications. Neurology. 35:1985;522-526
43. Marras C., Rochon P., Lang A.E. Predicting motor decline and disability in Parkinson disease. Arch. Neurol. 59:2002;1724-1728